Carisma Therapeutics Inc - Understand $carm stock

$CARM Market Cap: $41.54 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$20.69M

TTM

Gross Margin

Net Earnings

-$72.50M

TTM

Current Assets

$50.72M

Q2 2024

Current Liabilities

$15.62M

Q2 2024

Current Ratio

324.78%

Q2 2024

Total Assets

$59.34M

Q2 2024

Total Liabilities

$58.98M

Q2 2024

Book Value

$360.0K

Q2 2024

Cash

$40.36M

Q2 2024

P/E

-0.5730

Sep 18, 2024 EST

Free Cash Flow

-$76.52M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$14.90M	$40.00M	$26.50M	$11.20M	$0.00	$0.00	$0.00	$406.0K	$490.0K	$2.243M	$1.334M	$0.00	$0.00
YoY Change	-62.75%	50.94%	136.61%				-100.0%	-17.14%	-78.15%	68.14%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$14.90M	$40.00M	$26.50M	$11.20M	$0.00	$0.00	$0.00	$406.0K	$490.0K	$2.243M	$1.334M	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$29.53M	$39.79M	$29.39M	$14.30M	$12.21M	$11.62M	$8.070M	$14.74M	$9.850M	$8.470M	$4.010M	$4.210M	$3.270M
YoY Change	-25.8%	35.37%	105.55%	17.12%	5.08%	43.99%	-45.25%	49.64%	16.29%	111.22%	-4.75%	28.75%
% of Gross Profit
Research & Development	$74.13M	$38.59M	$25.31M	$29.19M	$24.66M	$14.08M	$12.51M	$13.48M	$26.34M	$26.70M	$13.79M	$15.26M	$9.410M
YoY Change	92.06%	52.47%	-13.29%	18.36%	75.2%	12.53%	-7.19%	-48.82%	-1.37%	93.67%	-9.66%	62.2%
% of Gross Profit
Depreciation & Amortization	$2.837M	$10.00K	$85.00K	$120.0K	$220.0K	$210.0K	$290.0K	$180.0K	$370.0K	$410.0K	$440.0K	$450.0K	$360.0K
YoY Change	28270.0%	-88.24%	-29.17%	-45.45%	4.76%	-27.59%	61.11%	-51.35%	-9.76%	-6.82%	-2.22%	25.0%
% of Gross Profit
Operating Expenses	$103.7M	$65.91M	$35.09M	$32.31M	$108.5M	$34.50M	$29.68M	$27.12M	$36.19M	$35.17M	$17.81M	$19.48M	$12.68M
YoY Change	57.26%	87.81%	8.6%	-70.22%	214.47%	16.24%	9.46%	-25.07%	2.88%	97.47%	-8.54%	53.6%
Operating Profit	-$88.73M	-$25.91M	-$8.549M	-$21.08M	-$108.5M	-$34.50M	-$29.26M	$2.866M	-$35.20M	-$32.93M	-$16.48M	-$19.48M
YoY Change	242.47%	203.06%	-59.44%	-80.57%	214.47%	17.93%	-1120.76%	-108.14%	6.88%	99.85%	-15.39%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$1.936M	$1.850M				$0.00	$0.00	-$247.0K	-$1.395M	-$376.0K	-$1.400M	-$168.0K	-$150.0K
YoY Change	4.65%						-100.0%	-82.29%	271.01%	-73.14%	733.33%	12.0%
% of Operating Profit								-8.62%
Other Income/Expense, Net		$296.0K	-$60.00K	$125.0K	$991.0K	$807.0K	$226.0K	-$970.0K	$1.744M	-$1.225M	-$1.547M	-$181.0K	$0.00
YoY Change		-593.33%	-148.0%	-87.39%	22.8%	257.08%	-123.3%	-155.62%	-242.37%	-20.81%	754.7%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$86.88M	-$23.76M	-$8.609M	-$20.95M	-$107.5M	-$33.69M	-$29.03M	$1.896M	-$33.45M	-$34.16M	-$18.03M	-$19.66M	-$12.83M
YoY Change	265.67%	175.98%	-58.91%	-80.51%	219.06%	16.07%	-1631.07%	-105.67%	-2.06%	89.44%	-8.29%	53.23%
Income Tax		-$3.875M	-$8.273M	$1.445M	$0.00	$0.00	$0.00	$5.000K	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income								0.26%
Net Earnings	-$86.88M	-$19.88M	-$336.0K	-$22.40M	-$107.5M	-$33.69M	-$29.03M	$1.891M	-$33.45M	-$34.16M	-$18.03M	-$19.66M	-$12.83M
YoY Change	336.93%	5817.86%	-98.5%	-79.17%	219.06%	16.07%	-1635.11%	-105.65%	-2.06%	89.49%	-8.3%	53.21%
Net Earnings / Revenue	-583.08%	-49.71%	-1.27%	-199.97%				465.76%	-6826.94%	-1522.78%	-1351.2%
Basic Earnings Per Share	-$2.59	-$0.10	$0.00	-$0.19	-$1.18	-$0.55	-$1.11	$0.09	-$1.76	-$2.37
Diluted Earnings Per Share	-$2.59	-$0.10	$0.00	-$0.19	-$1.18	-$0.55	-$1.11	$0.09	-$1.76	-$2.37	-$13.36M	-$11.99M	-$7.823M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$77.61M	$166.9M	$162.6M	$52.40M	$48.10M	$50.40M	$14.70M	$25.30M	$36.10M	$54.10M	$7.900M	$7.900M	$700.0K
YoY Change	-53.5%	2.62%	210.37%	8.94%	-4.56%	242.86%	-41.9%	-29.92%	-33.27%	584.81%	0.0%	1028.57%
Cash & Equivalents	$77.61M	$112.6M	$162.6M	$52.40M	$48.10M	$50.40M	$14.70M	$25.30M	$36.10M	$54.10M	$7.900M	$7.900M	$700.0K
Short-Term Investments	$0.00	$54.40M
Other Short-Term Assets	$2.866M	$21.40M	$18.48M	$10.50M	$6.300M	$1.300M	$300.0K	$600.0K	$200.0K	$300.0K	$100.0K	$400.0K	$300.0K
YoY Change	-86.61%	15.83%	75.96%	66.67%	384.62%	333.33%	-50.0%	200.0%	-33.33%	200.0%	-75.0%	33.33%
Inventory
Prepaid Expenses
Receivables		$0.00	$21.01M
Other Receivables		$800.0K	$3.482M
Total Short-Term Assets	$80.47M	$189.1M	$205.6M	$62.90M	$54.40M	$51.80M	$15.00M	$25.90M	$36.30M	$54.40M	$8.000M	$8.300M	$1.000M
YoY Change	-57.45%	-8.03%	226.88%	15.63%	5.02%	245.33%	-42.08%	-28.65%	-33.27%	580.0%	-3.61%	730.0%
Property, Plant & Equipment	$8.937M	$0.00	$43.00K	$100.0K	$200.0K	$300.0K	$500.0K	$800.0K	$400.0K	$500.0K	$800.0K	$1.200M	$1.500M
YoY Change		-100.0%	-57.0%	-50.0%	-33.33%	-40.0%	-37.5%	100.0%	-20.0%	-37.5%	-33.33%	-20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$146.0K	$0.00	$7.335M	$400.0K	$200.0K	$0.00	$100.0K	$0.00	$100.0K	$100.0K	$2.400M	$0.00	$100.0K
YoY Change		-100.0%	1733.75%	100.0%		-100.0%		-100.0%	0.0%	-95.83%		-100.0%
Total Long-Term Assets	$9.083M	$100.0K	$35.14M	$59.90M	$60.00M	$59.80M	$60.10M	$78.20M	$500.0K	$600.0K	$3.200M	$1.200M	$1.700M
YoY Change	8983.0%	-99.72%	-41.33%	-0.17%	0.33%	-0.5%	-23.15%	15540.0%	-16.67%	-81.25%	166.67%	-29.41%
Total Assets	$89.55M	$189.2M	$240.7M	$122.8M	$114.4M	$111.6M	$75.10M	$104.1M	$36.80M	$55.00M	$11.20M	$9.500M	$2.700M
YoY Change
Accounts Payable	$3.933M	$1.200M	$2.853M	$3.100M	$1.900M	$1.400M	$900.0K	$1.700M	$1.200M	$2.500M	$1.700M	$1.100M	$1.100M
YoY Change	227.75%	-57.94%	-7.97%	63.16%	35.71%	55.56%	-47.06%	41.67%	-52.0%	47.06%	54.55%	0.0%
Accrued Expenses	$8.988M	$29.40M	$8.370M	$4.200M	$6.200M	$4.700M	$3.800M	$1.600M	$1.800M	$2.000M	$900.0K	$500.0K	$600.0K
YoY Change	-69.43%	251.25%	99.29%	-32.26%	31.91%	23.68%	137.5%	-11.11%	-10.0%	122.22%	80.0%	-16.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$544.0K							$0.00	$4.100M	$300.0K	$1.600M	$200.0K	$600.0K
YoY Change								-100.0%	1266.67%	-81.25%	700.0%	-66.67%
Total Short-Term Liabilities	$15.91M	$31.00M	$11.57M	$18.00M	$8.500M	$6.100M	$4.700M	$4.000M	$7.600M	$5.200M	$5.400M	$1.800M	$2.200M
YoY Change	-48.68%	167.98%	-35.73%	111.76%	39.34%	29.79%	17.5%	-47.37%	46.15%	-3.7%	200.0%	-18.18%
Long-Term Debt	$328.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$9.800M	$9.700M	$2.900M	$1.800M	$400.0K
YoY Change								-100.0%	1.03%	234.48%	61.11%	350.0%
Other Long-Term Liabilities	$46.79M	$0.00	$53.50M	$101.5M	$120.0M	$48.70M	$39.80M	$45.10M	$500.0K	$3.200M	$700.0K	$200.0K	$200.0K
YoY Change		-100.0%	-47.29%	-15.42%	146.41%	22.36%	-11.75%	8920.0%	-84.38%	357.14%	250.0%	0.0%
Total Long-Term Liabilities	$47.11M	$0.00	$53.50M	$101.5M	$120.0M	$48.70M	$39.80M	$45.10M	$10.30M	$12.90M	$3.600M	$2.000M	$600.0K
YoY Change		-100.0%	-47.29%	-15.42%	146.41%	22.36%	-11.75%	337.86%	-20.16%	258.33%	80.0%	233.33%
Total Liabilities	$63.02M	$31.00M	$69.04M	$132.1M	$141.1M	$67.40M	$57.10M	$65.40M	$17.90M	$18.20M	$8.900M	$3.800M	$2.800M
YoY Change	103.3%	-55.1%	-47.74%	-6.38%	109.35%	18.04%	-12.69%	265.36%	-1.65%	104.49%	134.21%	35.71%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Basic Shares Outstanding	33.52M shares	200.5M shares	182.3M shares	118.2M shares	90.93M shares	61.77M shares	26.11M shares	21.08M shares	18.99M shares	14.64M shares
Diluted Shares Outstanding	33.52M shares	200.5M shares	182.3M shares	118.2M shares	90.93M shares	61.77M shares	26.11M shares	21.73M shares	18.99M shares	14.64M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $41.545 Million

About Carisma Therapeutics Inc

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2014-02-06. The company is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Industry: Pharmaceutical Preparations Peers: Assembly Biosciences Inc Surrozen Inc Marizyme Inc HOOKIPA Pharma Inc Lumos Pharma Inc Dianthus Therapeutics Inc NextCure Inc Reneo Pharmaceuticals Inc Xilio Therapeutics Inc